CA2899308C - Compositions d'especes d'adalimumab a faible teneur en acide et utilisations associees - Google Patents

Compositions d'especes d'adalimumab a faible teneur en acide et utilisations associees Download PDF

Info

Publication number
CA2899308C
CA2899308C CA2899308A CA2899308A CA2899308C CA 2899308 C CA2899308 C CA 2899308C CA 2899308 A CA2899308 A CA 2899308A CA 2899308 A CA2899308 A CA 2899308A CA 2899308 C CA2899308 C CA 2899308C
Authority
CA
Canada
Prior art keywords
adalimumab
pharmaceutical composition
less
composition
acidic species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2899308A
Other languages
English (en)
Other versions
CA2899308A1 (fr
Inventor
Natarajan Ramasubramanyan
Lihua Yang
Matthew Omon HERIGSTAD
Hong Yang
Kartik Subramanian
Diane D. Dong
Wen Chung Lim
Kathreen A. Gifford
Zehra Kaymakcalan
Xiaobei ZENG
Christopher Chumsae
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2013/031681 external-priority patent/WO2013158279A1/fr
Priority claimed from PCT/US2013/031485 external-priority patent/WO2013158275A1/fr
Application filed by AbbVie Inc filed Critical AbbVie Inc
Priority to CA2926384A priority Critical patent/CA2926384A1/fr
Priority to CA2926301A priority patent/CA2926301A1/fr
Publication of CA2899308A1 publication Critical patent/CA2899308A1/fr
Application granted granted Critical
Publication of CA2899308C publication Critical patent/CA2899308C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Water Supply & Treatment (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2899308A 2013-03-14 2013-10-18 Compositions d'especes d'adalimumab a faible teneur en acide et utilisations associees Expired - Fee Related CA2899308C (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2926384A CA2926384A1 (fr) 2013-03-14 2013-10-18 Compositions d'especes faiblement acides et leurs procedes de production et d'utilisation
CA2926301A CA2926301A1 (fr) 2013-03-14 2013-10-18 Compositions d'especes faiblement acides et leurs procedes de production et d'utilisation

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2013/031681 WO2013158279A1 (fr) 2012-04-20 2013-03-14 Procédés de purification de protéines pour réduire des espèces acides
PCT/US2013/031485 WO2013158275A1 (fr) 2012-04-20 2013-03-14 Procédés de culture cellulaire pour réduire des espèces acides
USPCT/US2013/031485 2013-03-14
USPCT/US2013/031681 2013-03-14
PCT/US2013/065749 WO2014158231A1 (fr) 2013-03-14 2013-10-18 Compositions d'espèces faiblement acides et leurs procédés de production et d'utilisation

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CA2926384A Division CA2926384A1 (fr) 2013-03-14 2013-10-18 Compositions d'especes faiblement acides et leurs procedes de production et d'utilisation
CA2926301A Division CA2926301A1 (fr) 2013-03-14 2013-10-18 Compositions d'especes faiblement acides et leurs procedes de production et d'utilisation

Publications (2)

Publication Number Publication Date
CA2899308A1 CA2899308A1 (fr) 2014-10-02
CA2899308C true CA2899308C (fr) 2017-04-18

Family

ID=49517725

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2926384A Abandoned CA2926384A1 (fr) 2013-03-14 2013-10-18 Compositions d'especes faiblement acides et leurs procedes de production et d'utilisation
CA2899308A Expired - Fee Related CA2899308C (fr) 2013-03-14 2013-10-18 Compositions d'especes d'adalimumab a faible teneur en acide et utilisations associees
CA2926301A Abandoned CA2926301A1 (fr) 2013-03-14 2013-10-18 Compositions d'especes faiblement acides et leurs procedes de production et d'utilisation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2926384A Abandoned CA2926384A1 (fr) 2013-03-14 2013-10-18 Compositions d'especes faiblement acides et leurs procedes de production et d'utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2926301A Abandoned CA2926301A1 (fr) 2013-03-14 2013-10-18 Compositions d'especes faiblement acides et leurs procedes de production et d'utilisation

Country Status (8)

Country Link
EP (1) EP2836515A1 (fr)
KR (1) KR20150129033A (fr)
AU (1) AU2013384204B2 (fr)
BR (1) BR112015017307A2 (fr)
CA (3) CA2926384A1 (fr)
HK (1) HK1206755A1 (fr)
SG (1) SG11201504260UA (fr)
WO (1) WO2014158231A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12529024B2 (en) 2019-11-15 2026-01-20 Lonza Ltd Process and system for producing an inoculum

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de purification de protéines pour réduire des espèces acides
WO2013158273A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3057616B1 (fr) 2013-10-16 2020-03-11 Outlook Therapeutics, Inc. Formulations de tampon pour stabilité d'anticorps améliorée
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US20160039924A1 (en) * 2014-08-05 2016-02-11 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
WO2016118707A1 (fr) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation de variants de charge dans une composition d'anticorps monoclonaux
DK3334747T5 (da) 2015-08-13 2024-10-07 Amgen Inc Ladet dybdefiltrering af antigenbindende proteiner
KR20180037275A (ko) * 2015-08-24 2018-04-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 생물제약 조성물
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
GB201602938D0 (en) * 2016-02-19 2016-04-06 Ucb Biopharma Sprl Protein purification
WO2018027195A1 (fr) * 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions contenant des quantités réduites d'isoformes acides de daclizumab et procédés de préparation associés
US11020686B2 (en) 2016-08-16 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
KR20190053908A (ko) 2016-09-16 2019-05-20 로이코케어 아게 가공 동안 바이오 의약품의 안정화를 위한 신규한 방법
US11166915B2 (en) 2016-09-16 2021-11-09 Leukocare Ag Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
JP7102401B2 (ja) 2016-10-25 2022-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド クロマトグラフィーデータ解析のための方法およびシステム
EP3339444A1 (fr) * 2016-12-20 2018-06-27 Mabxience Research, S.L. Procédé permettant d'obtenir une glycoprotéine ayant un pourcentage élevé de glycanes afucosylés
GB201711481D0 (en) 2017-07-17 2017-08-30 Ucb Biopharma Sprl Protein purification
CA3073935A1 (fr) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals, Inc. Procedes de reduction de la formation de particules et compositions formees par ceux-ci
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
CN111693711B (zh) * 2019-03-12 2023-05-05 上海市质量监督检验技术研究院 一种超高压液相色谱串联质谱同时检测鲜蛋中103种抗生素残留的方法
WO2021126657A1 (fr) * 2019-12-18 2021-06-24 Tesaro, Inc. Compositions biopharmaceutiques et procédés associés
WO2022154762A1 (fr) * 2021-01-18 2022-07-21 Turgut İlaçlari A.Ş. Procédé de production d'adalimumab
EP4720085A1 (fr) * 2023-05-30 2026-04-08 Mabxience Research, S.L. Procede de purification d'immunoglobulines

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2095633C (fr) 1990-12-03 2003-02-04 Lisa J. Garrard Methode d'enrichissement de proteines variantes aux proprietes liantes alterees
EP1820858B1 (fr) 1991-03-01 2009-08-12 Dyax Corporation Protéine chimère comprenant des micro-protéines dotées de deux liaisons disulfure ou plus et ses modes de réalisation
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU682670B2 (en) 1993-02-05 1997-10-16 Becton Dickinson & Company Syringe needle isolation device
US5607400A (en) 1995-05-19 1997-03-04 Becton, Dickinson And Company Pre-fillable syringe and stopper assembly therefor
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
JPH09173450A (ja) 1995-12-26 1997-07-08 Nissho Corp プレフィルドシリンジ
MX336813B (es) 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
JP3293122B2 (ja) 1996-12-13 2002-06-17 ニプロ株式会社 プレフィルドシリンジ
SE9703425D0 (sv) 1997-09-23 1997-09-23 Pharmacia & Upjohn Ab Prefilled ampooules and manufacture thereof
DE19751219A1 (de) 1997-11-19 1999-05-27 Vetter & Co Apotheker Spritze, insbesondere vorgefüllte Spritze, oder Karpule
EP2253548A1 (fr) 1998-03-13 2010-11-24 Becton, Dickinson and Company Méthode pour la production, remplissage et emballage de récipients médicaux
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
JP3591636B2 (ja) 2000-04-03 2004-11-24 ニプロ株式会社 プレフィルドシリンジ
CN1789416B (zh) 2001-05-11 2011-11-16 协和发酵麒麟株式会社 含人抗体λ轻链基因的人类人工染色体
JP4141156B2 (ja) 2002-03-15 2008-08-27 日本ベクトン・ディッキンソン株式会社 プランジャ後退制限機構付きプレフィルドシリンジ
WO2003087327A2 (fr) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Conservation de matieres bio-actives au moyen de mousse lyophilisee
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
WO2003087335A2 (fr) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Conservation de matieres bioactives par sechage par pulverisation
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
WO2004004811A1 (fr) 2002-07-02 2004-01-15 Terumo Kabushiki Kaisha Seringue et seringue preremplie
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
DE10254321A1 (de) 2002-11-21 2004-06-17 Arzneimittel Gmbh Apotheker Vetter & Co. Ravensburg Vorgefüllte Spritze
US20040162414A1 (en) * 2002-11-22 2004-08-19 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
CN1745170A (zh) 2002-12-17 2006-03-08 米迪缪尼疫苗股份有限公司 生物活性材料的高压喷雾干燥
JP2004229750A (ja) 2003-01-28 2004-08-19 Nipro Corp プレフィルドシリンジ及びそのバレルの製造方法
AR044302A1 (es) 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
US20050075611A1 (en) 2003-10-01 2005-04-07 Hetzler Kevin G. Low extractable, thermoplastic syringe and tip cap
CN103336129A (zh) 2005-11-01 2013-10-02 阿布维生物技术有限公司 使用生物标志物诊断强直性脊柱炎的方法和组合物
US7988675B2 (en) 2005-12-08 2011-08-02 West Pharmaceutical Services Of Delaware, Inc. Automatic injection and retraction devices for use with pre-filled syringe cartridges
JP4682850B2 (ja) 2006-01-12 2011-05-11 ニプロ株式会社 プレフィルドシリンジ
CN102887955A (zh) 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
ES2442258T3 (es) 2006-10-27 2014-02-10 Abbvie Biotechnology Ltd Anticuerpos cristalinos anti-hTNF alfa
WO2008150491A2 (fr) 2007-05-31 2008-12-11 Abbott Laboratories Biomarqueurs prédictifs de la réactivité aux inhibiteurs tnfα dans des troubles auto-immuns
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
TWI478937B (zh) 2008-01-15 2015-04-01 Abbvie Inc 改良之哺乳動物表現載體及其用途
CA2797356C (fr) 2010-04-26 2020-12-29 Novartis Ag Milieu de culture cellulaire ameliore
US8821865B2 (en) 2010-11-11 2014-09-02 Abbvie Biotechnology Ltd. High concentration anti-TNFα antibody liquid formulations
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
WO2013158279A1 (fr) * 2012-04-20 2013-10-24 Abbvie Inc. Procédés de purification de protéines pour réduire des espèces acides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12529024B2 (en) 2019-11-15 2026-01-20 Lonza Ltd Process and system for producing an inoculum

Also Published As

Publication number Publication date
CA2899308A1 (fr) 2014-10-02
CA2926384A1 (fr) 2014-10-02
CA2926301A1 (fr) 2014-10-02
SG11201504260UA (en) 2015-10-29
WO2014158231A1 (fr) 2014-10-02
EP2836515A1 (fr) 2015-02-18
AU2013384204A1 (en) 2015-06-04
AU2013384204B2 (en) 2017-03-16
HK1206755A1 (en) 2016-01-15
BR112015017307A2 (pt) 2017-11-21
KR20150129033A (ko) 2015-11-18

Similar Documents

Publication Publication Date Title
CA2899308C (fr) Compositions d'especes d'adalimumab a faible teneur en acide et utilisations associees
US9522953B2 (en) Low acidic species compositions and methods for producing and using the same
US9017687B1 (en) Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8946395B1 (en) Purification of proteins using hydrophobic interaction chromatography
AU2013381759B2 (en) Modulated lysine variant species compositions and methods for producing and using the same
US9499616B2 (en) Modulated lysine variant species compositions and methods for producing and using the same
WO2014143185A1 (fr) Purification de protéines au moyen de la chromatographie d'interaction hydrophobe
US20190062419A1 (en) Protein purification methods to reduce acidic species
US20140154270A1 (en) Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
EP2968532A1 (fr) Purification de protéines au moyen de la chromatographie d'interaction hydrophobe
CA2899449A1 (fr) Composition d'especes faiblement acides et leurs methodes de production utilisant la chromatographie de deplacement

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150724

MKLA Lapsed

Effective date: 20191018